Commentary

The FDA has approved remdesivir for severe COVID-19 in children and adults. This commentary reviews potential interactions of remdesivir with psychotropic medications.

This commentary discusses the challenges faced by health care providers in psychiatric wards during the COVID-19 pandemic.

Various novel pharmacologic treatments are being considered for COVID-19. The authors of this commentary briefly discuss some of these proposed treatments and their possible psychiatric adverse effects.

Read commentary on inadequate antidepressant response for MDD. Determining where patients are on the response continuum and managing inadequate response.

This commentary explores the association between past viral outbreaks and suicide to highlight current and future challenges patients may face in response to the COVID-19 pandemic.

This commentary notes the findings and implications of a recent study by Rommel et al and discusses possible risks of perinatal antidepressant treatment in light of the need to...